首页> 美国卫生研究院文献>Gland Surgery >Approach to cytological indeterminate thyroid nodules
【2h】

Approach to cytological indeterminate thyroid nodules

机译:细胞学上不确定的甲状腺结节的方法

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务,本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文,但由于OA文献来源多样且变更频繁,仍可能出现获取不到、文献不完整或与标题不符等情况,如果获取不到我们将提供退款服务。请知悉。

摘要

The indeterminate thyroid nodules diagnosed by fine-needle aspiration cytology (FNAC)represents a problem for both cytopathologists and clinicians. The former sometimes use this diagnostic category as a sort of basket, putting in cases that they do not know exactly how to classify. The latter are faced with a highly variable risk of malignancy and consequently the management remains a challenge. On the histopathological side, the new WHO classification of tumors of the thyroid introduced the concept of tumors with uncertain and low malignant potential, and the concept of non-invasive follicular thyroid neoplasm with papillary-like nuclear features (NIFTP), whose prognosis and management are still to be completely elucidated. While the risk of malignancy of the indeterminate diagnostic category has decreased due to the re-classification of certain types of papillary thyroid carcinomas of the follicular variant into a low malignant potential form (the NIFTP), cases diagnosed cytologically as indeterminate will probably increase in the future to avoid false positive diagnosis. Thus, the indeterminate thyroid diagnostic category still remains a challenge, both at the diagnostic level and for its management. The new version of the Bethesda system for reporting thyroid cytopathology suggests managing these patients with a repeat FNA, diagnostic lobectomy and/or molecular testing.
机译:通过细针穿刺细胞学(FNAC)诊断出的不确定的甲状腺结节对细胞病理学家和临床医生而言都是一个难题。前者有时将此诊断类别用作一种篮子,以防万一他们不清楚确切的分类方法。后者面临着高度可变的恶性风险,因此管理仍然是一个挑战。在组织病理学方面,新的WHO甲状腺肿瘤分类引入了具有不确定性和低恶性潜力的肿瘤概念,以及具有乳头状核特征的非侵入性滤泡性甲状腺肿瘤(NIFTP)概念,其预后和管理还有待完全阐明。尽管由于某些类型的滤泡性甲状腺乳头状甲状腺癌重新分类为低恶性潜能形式(NIFTP),不确定的诊断类别的恶性风险有所降低,但在细胞学上被诊断为不确定的病例可能会增加。以后避免假阳性诊断。因此,不确定的甲状腺诊断类别无论在诊断水平还是在其管理上仍然是一个挑战。用于报告甲状腺细胞病理学的Bethesda系统的新版本建议通过重复FNA,诊断性肺叶切除术和/或分子检测来管理这些患者。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
代理获取

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号